Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERASNASDAQ:IVVDNASDAQ:MREONASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.22+0.8%$1.32$1.01▼$3.45$345.61M1.121.75 million shs933,416 shsIVVDInvivyd$0.75-1.6%$0.63$0.35▼$2.74$89.79M0.44.48 million shs5.59 million shsMREOMereo BioPharma Group$2.24-1.8%$2.29$1.58▼$5.02$362.52M0.531.12 million shs568,594 shsRGNXREGENXBIO$9.71-1.5%$7.82$5.04▼$15.39$487.05M1.11882,966 shs645,180 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca0.00%-5.06%-12.86%-13.78%-50.00%IVVDInvivyd0.00%-3.63%+11.98%-57.71%-65.35%MREOMereo BioPharma Group0.00%0.00%-11.81%-21.54%-25.08%RGNXREGENXBIO0.00%+9.22%+5.54%+33.56%-37.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.5621 of 5 stars4.52.00.00.02.72.51.3IVVDInvivyd2.884 of 5 stars3.62.00.00.01.73.31.3MREOMereo BioPharma Group1.7421 of 5 stars3.62.00.00.01.71.70.0RGNXREGENXBIO4.1723 of 5 stars3.42.00.04.62.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57274.71% UpsideIVVDInvivyd 3.25Buy$7.52904.23% UpsideMREOMereo BioPharma Group 3.25Buy$7.71244.39% UpsideRGNXREGENXBIO 2.83Moderate Buy$31.63225.70% UpsideCurrent Analyst Ratings BreakdownLatest IVVD, RGNX, MREO, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025IVVDInvivydD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/17/2025RGNXREGENXBIOThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/27/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$7.003/26/2025ERASErascaRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.003/26/2025IVVDInvivydHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/26/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/21/2025ERASErascaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $3.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$2.10 per shareN/AIVVDInvivyd$36.69M2.45N/AN/A$1.61 per share0.46MREOMereo BioPharma Group$1M356.16N/AN/A$0.36 per share6.22RGNXREGENXBIO$156.72M3.11N/AN/A$7.09 per share1.37Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)IVVDInvivyd-$198.64M-$1.20N/A6.80N/AN/A-155.33%-114.88%8/13/2025 (Estimated)MREOMereo BioPharma Group-$29.47M-$0.07N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)RGNXREGENXBIO-$263.49M-$3.11N/AN/AN/A-283.19%-70.65%-41.68%8/7/2025 (Estimated)Latest IVVD, RGNX, MREO, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IVVDInvivyd-$0.04-$0.14-$0.10-$0.14$34.45 million$11.30 million5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/12/2025Q1 2025RGNXREGENXBIO$0.41$0.12-$0.29$0.12$105.35 million$89.01 million3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/A3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A3/20/2025Q4 2024IVVDInvivyd-$0.25-$0.15+$0.10-$0.15$13.57 million$13.80 million3/13/2025Q4 2024RGNXREGENXBIO-$1.27-$1.01+$0.26-$1.01$23.70 million$21.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AIVVDInvivydN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A11.0011.00IVVDInvivydN/A1.921.58MREOMereo BioPharma GroupN/A6.106.10RGNXREGENXBION/A3.053.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%IVVDInvivyd70.36%MREOMereo BioPharma Group62.83%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%IVVDInvivyd25.40%MREOMereo BioPharma Group5.50%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million221.94 millionOptionableIVVDInvivyd100119.96 million98.21 millionOptionableMREOMereo BioPharma Group40159.00 million148.74 millionOptionableRGNXREGENXBIO37050.16 million43.04 millionOptionableIVVD, RGNX, MREO, and ERAS HeadlinesRecent News About These CompaniesBNP Paribas Financial Markets Acquires 75,652 Shares of REGENXBIO Inc. (NASDAQ:RGNX)May 25 at 3:18 AM | marketbeat.comQ2 Earnings Forecast for REGENXBIO Issued By Leerink PartnrsMay 24 at 7:37 AM | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Jane Street Group LLCMay 23 at 3:10 AM | marketbeat.comRegenxbio at RBC Conference: Strategic Moves and Clinical ProgressMay 22 at 11:45 AM | investing.comREGENXBIO FY2025 EPS Forecast Reduced by Chardan CapitalMay 21, 2025 | marketbeat.comREGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 20, 2025 | finanznachrichten.deREGENXBIO announces royalty monetization agreement for up to $250MMay 20, 2025 | msn.comREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionMay 19, 2025 | prnewswire.comFY2025 EPS Estimate for REGENXBIO Decreased by AnalystMay 19, 2025 | americanbankingnews.comPoint72 Asia Singapore Pte. Ltd. Makes New $447,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)May 18, 2025 | marketbeat.comComparing Novavax (NASDAQ:NVAX) and REGENXBIO (NASDAQ:RGNX)May 17, 2025 | americanbankingnews.comQ2 Earnings Estimate for REGENXBIO Issued By HC WainwrightMay 17, 2025 | americanbankingnews.comHudson Bay Capital Management LP Has $2.38 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)May 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for REGENXBIO Q2 Earnings?May 16, 2025 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in StockMay 15, 2025 | insidertrades.comUS FDA accepts and grants priority review status to Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis IIMay 15, 2025 | pharmabiz.comEarnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their ForecastsMay 15, 2025 | finance.yahoo.comFDA Accepts Biologics License Application for Mucopolysaccharidosis II TreatmentMay 14, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Integral Health Asset Management LLCMay 14, 2025 | marketbeat.comFDA Grants Regenxbio Priority Review for MPS II Gene Therapy Regulatory ApplicationMay 13, 2025 | precisionmedicineonline.comRegenxbio stock rises on FDA’s priority review for MPS II therapyMay 13, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVVD, RGNX, MREO, and ERAS Company DescriptionsErasca NASDAQ:ERAS$1.22 +0.01 (+0.83%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.22 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Invivyd NASDAQ:IVVD$0.75 -0.01 (-1.58%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.73 -0.02 (-2.47%) As of 05/23/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Mereo BioPharma Group NASDAQ:MREO$2.24 -0.04 (-1.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.24 +0.00 (+0.22%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.REGENXBIO NASDAQ:RGNX$9.71 -0.15 (-1.52%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.91 +0.20 (+2.05%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
